Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Other Non-Current Liabilities (2016 - 2026)

Eledon Pharmaceuticals filings provide 2 years of Other Non-Current Liabilities readings, the most recent being $3.4 million for Q4 2016.

  • On a quarterly basis, Other Non-Current Liabilities rose 3817.05% to $3.4 million in Q4 2016 year-over-year; TTM through Dec 2016 was $3.4 million, a 3817.05% increase, with the full-year FY2016 number at $3.4 million, up 3817.05% from a year prior.
  • Other Non-Current Liabilities hit $3.4 million in Q4 2016 for Eledon Pharmaceuticals, up from $126000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $3.4 million in Q4 2016 to a low of $13000.0 in Q2 2015.